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ABSTRACT
Liver test abnormalities are commonly found in ambulatory patients. The liver function tests are routinely 
included in chemistry panels. According to the American Gastroenterological Association (AGA), 1-4% of 
the asymptomatic population may have elevated serum liver chemistry. The majority of asymptomatic patients 
with liver test abnormalities have no evidence of liver disease. Unfortunately, abnormal results for liver function 
are often not adequately investigated, missing an important chance of identifying treatable chronic liver disease. 
Potential causes of liver aminotransferase elevation are originated from hepatic causes (viral hepatitis, alcohol 
use, medication use, steatosis and non-alcoholic steatosis hepatitis, autoimmune hepatitis, hemochromatosis, 
Wilson’s disease, α-antitrypsin deficiency) and non hepatic causes. In the majority patients (92%) with chronically 
elevated aminotransferase tests, etiologies of the liver disease could be diagnosed through close clinical approach, 
which includes: history taking, physical examination, and blood tests. If elevation persists after an appropriate 
period of observation, further testing may include ultrasonography and other serum studies. In about 8% of 
patients with chronic abnormal alanine aminotransferase levels no cause is found. So, if liver test abnormalities 
cannot be explained by other findings, liver biopsy examination can help to exclude serious liver disease or 
disclose the nature and severity of liver disease. 
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ABSTRAK
Gangguan tes fungsi hati cukup sering dijumpai pada pasien rawat jalan. Berdasarkan the American 
Gastroenterological Association (AGA), 1-4% dari populasi yang tidak mengalami keluhan mengalami 
peningkatan enzim hati. Mayoritas dari pasien tersebut ternyata terbukti tidak menderita penyakit hati. Namun 
gangguan fungsi hati yang terjadi sering tidak diinvestigasi secara memadai, sehingga penyakit hati kronis 
yang bersifat dapat disembuhkan tidak dapat teridentifikasi. Penyebab peningkatan aminotransferase dapat 
berasal dari virus hepatitis, alkohol,obat-obatan, steatosis dan non alkoholik steatohepatitis, hepatitis autoimun, 
hemokromatosis, penyakit Wilson, dan defisiensi α-antitripsin. Melalui pendekatan klinis yang tepat, 92% 
pasien yang mengalami peningkatan aminotransferase kronis dapat diketahui etiologinya, melalui anamnesis, 
pemeriksaan fisik dan laboratorium. Apabila kadar aminotransferase masih meningkat diperlukan pemeriksaan 
ultrasonografi dan pemeriksaan laboratorium lainnya. Sedangkan sejumlah 8% pasien dengan peningkatan kronis 
aminotransferase tidak diketahui penyebabnya. Apabila penyebab peningkatan aminotrasferase masih belum 
ditemukan maka diperlukan pemeriksaan biopsi hati untuk menyingkirkan adanya penyakit hati yang serius. 
Kata kunci: peningkatan enzim hati transaminase, pasien tanpa gejala, penyakit hati kronis
INTRODUCTION
Normal laboratory values are defined as the mean of 
the distribution ± 2 standard deviations of the normal 
population. Therefore, by definition, 5% of normal 
patients will have abnormalities of any given test (2.5% 
are above and 2.5% are below 2 standard deviation). 
Normal laboratory values may vary according to age, 
sex, blood group, and postprandial state as well as other 
factors. If the result of laboratory values is normal or 
slightly increase, it does not ensure that the patient is 
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free from the disease.1 Liver disease is often reflected 
by abnormal results of at least one of the liver function 
test (serum liver enzymes). These serum liver enzymes 
are commonly referred to liver function tests, though 
they actually reflect hepatocyte integrity or presence 
of cholestasis rather than liver function.2 
In 1989, a panel of 12 European and American 
experts by consensus defined liver injury as an 
increase of more than twice the upper limit of the 
normal range of alanine aminotransferase (ALT) 
or conjugated bilirubin, or a combined increase of 
aspartate transaminase (AST), alkaline phosphatase 
(ALP), and total bilirubin.3 Isolated alterations of 
biochemical markers of liver damage in seemingly 
healthy patient can present a challenge for the clinician. 
Mild elevation in liver chemistry tests, such as ALT 
and AST can reveal serious underlying disease or have 
transient and benign etiologies. These liver chemistry 
tests often are part of standard laboratory panels in 
asymptomatic outpatients, similar to screening test for 
blood donors and for life insurance applicants.2
According to the American Gastroenterological 
Association (AGA), 1-4% of the asymptomatic 
population may have elevated serum liver chemistry.1 
Kundrotas et al, conducted a study in a population 
of asymptomatic US Air Force basis trainee blood 
donors. Of 44,160 individuals screened, 19,877 (45%) 
voluntarily donated blood, 99 (0.5%) of which had 
confirmed ALT elevation (ALT > 2.25 standard deviation 
or ALT > 55 IU/L). Abnormal results for liver function 
are often not adequately investigated, missing an 
important chance of identifying treatable chronic liver 
disease.4 Sherwood et al, underwent a study to determine 
whether abnormal results for liver function test were 
investigated in primary care and findings on full 
investigation. Of 8,208 tests for liver function requested 
by doctors in the six months period, they identified 873 
patients with abnormal results (γ-glutamyltransferase, 
alkaline phosphatase and ALT concentrations at least 
twice the upper limit of the reference range). Of 873 
patients, 157 (18%) were not appropriately followed up. 
With the reason, this article reviews the interpretation 
and how to manage an asymptomatic patient with mild 
elevation of liver aminotransferase levels.5
AMINOTRANSFERASE ENZYME
Aminotransferases (ALT and AST) constitute 
a group of enzymes that catalyze the interconversion 
of amino acids and alpha-oxoacids by transfer of 
amino groups. These enzymes have been suggested as 
enzymes of greatest clinical significance. 
Aspartate aminotransferase (AST) is one of 
the most active enzymes in the cell, which exists in 
mitochondrial and cytosolic variants, and the detailed 
iso-enzyme pattern is tissue-specific. Besides in liver 
cells, AST is also abundantly expressed in several non 
hepatic tissues including heart, skeletal muscle, and 
blood, kidney, pancreas, spleen, lung and erythrocytes. 
AST escapes in large amounts from dead or dying 
tissues and enters the bloodstream. Therefore, it is often 
measured in blood samples for medical diagnostic 
purpose and evaluation of liver and heart disease. 
Alanine aminotransferase (ALT) exists in 
mitochondrial and cytosolic variants. The detailed iso-
enzyme pattern is tissue-specific. High concentrations 
of ALT are found in the liver, and relatively low 
concentrations are found in the heart, muscle and 
kidney. So it is frequently considered specific for 
hepatocelullar injury. It escapes in large amounts from 
dead or dying tissues and ALT may be measured in 
blood samples for medical diagnostic purposes and to 
monitor the course of treatment for hepatitis. Injury 
to the liver, whether acute or chronic, eventually 
results in an increase in serum concentrations of 
aminotransferases. Increased serum levels of ALT 
and AST indicate hepatocyte injury and necrosis. The 
increase of absolute level of these aminotransferases 
(enzymes) in serum does not correlate with the extent 
of the hepatocellular injury and is neither specific for 
the cause of liver disease nor predictive of outcome.2,6
There are four major types of liver injury: 
hepatocellular, autoimmune, cholestasis and 
infiltrative. The predominant laboratory abnormality 
defines the pattern of injury. A hepatocellular pattern 
is marked by isolated or predominant elevations 
of serum transaminase. Cholestasis and infiltrative 
patterns, in contrast, have elevation in serum alkaline 
phosphatase with normal or mild elevations in serum 
aminotransferase. An autoimmune mechanism 
can present with either a hepatocellular pattern if 
hepatocytes are involved (autoimmune hepatitis) 
or cholestatis if the immune mechanism targets the 
billiary ducts (e.g. primary billiary cirrhosis).7
The measurement of serum aminotransferase 
levels has been in clinical practice for 50 years, and 
the normal values have not changed. However, recent 
studies from Italy, Sweden, and France have shown that 
increased ALT levels not only indicate hepatocellular 
damage, but also correlate independently with sex, 
body mass index (BMI), and abnormal lipid and 
carbohydrate metabolism, and strenuous exercise.2,7,8
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Serum ALT activity, the variable most commonly 
measured to assess hepatic disease, fails to identify many 
patients with hepatic injury. Prati et al, proposed to revise 
the upper limit of normal value for ALT to improve 
the sensitivity of this test in identifying subclinical liver 
disease.9 Current upper limit for ALT is 30 U/L for 
female and 40 U/L for male. This study redefined ALT 
limits in blood donors at low risk for non-alcoholic fatty 
liver disease (NAFLD) and without hepatitis B or C to 
19 U/L for female and 30 U/L for male. When applied 
to 209 anti HCV positive donors, the new thresholds had 
76.3% sensitivity and 88.5% specificity in identifying 
patients with hepatitis C viremia compared with 55% 
and 97.4% for previous thresholds. 
The magnitude of aminotransferase alteration can 
be classified as mild, moderate and very high.2,6 Very 
high aminotransferase enzyme (> 15-fold the upper 
normal limit) are typically seen in acute viral hepatitis, 
toxin or drugs induced liver damage, ischemic hepatitis, 
hepatic artery ligation and fulminant Wilson’s disease. 
Moderate increase of aminotransferase (5-10-fold) can 
be seen in many form of acute and chronic liver disease, 
including viral and autoimmune hepatitis, alcoholic 
hepatitis, and hepatic injury caused by metabolic 
diseases, such as hemochromatosis or Wilson’s disease. 
Mild increase (< 5-fold) aminotransferase levels can 
be seen in many causes (Table 1).
It is not always possible to distinguish acute from 
chronic hepatic injury according to the aminotransferase 
levels. Although chronic hepatic injury is defined 
pathologically, patients with abnormal liver function 
test ALT for > 6 months are considered to have chronic 
hepatic injury. Most patients with chronic hepatitis C 
(the most common form of chronic hepatic injury) 
have ALT values one to four times the upper reference 
limit and 90% have maximum ALT less than seven 
times the upper reference limit. The best values for 
recognizing acute hepatic injury were 200 U/L for 
AST with sensitivity of 91% and specificity of 95%, 
while 300 U/L for ALT with sensitivity of 96% and 
specificity of 94%.10
ETIOLOGY OF MILD AMINOTRANSFERASE  
ELEVATION
The most common etiologies for chronic liver 
amonitransferase levels are alcohol use, non-alcoholic 
fatty liver disease, viral hepatitis, and other rare 
etiologies (autoimmune hepatitis, hereditary liver 
diseases).5,11,12 Chronic hepatitis C was diagnosed 
in 15.3% of patients, alcoholic liver disease in 8%, 
autoimmune hepatitis, primary billiary cirrhosis in 
1.3% each, α-1 antitrypsin deficiency in 0.7%, and 
non-alcoholic steatohepatitis and or steatosis in 
42%, and 36 (24%) patients had chronic hepatitis of 
unknown origin.13 The cause of an elevated alanine 
amonitransferase levels may be divided into hepatic 
causes and nonhepatic causes (Table 1). 
NON-ALCOhOLIC FATTY LIVER DISEASE
There are 2 histologic patterns of non-alcoholic 
fatty liver disease (NAFLD): non-alcoholic fatty 
liver and non-alcoholic steatohepatitis (NASH). 
NAFLD is the most common cause for unexplained 
persistent elevation of ALT level once hepatitis C 
and other known causes of chronic liver disease have 
been excluded. Most patients with NAFLD in cross 
sectional studies are asymptomatic. Obesity is the most 
common abnormality on physical examination and is 
present in 30-100% patients. Most patients with NASH 
(50-90%) have abnormal aminotransferase activities. 
The degree of enzyme elevation is between 1 and 4 
times the upper limit of normal values. There is no 
accurate noninvasive method to diagnose NASH. There 
are four sonographic findings of diffuse fatty change 
in the liver: (1) a diffuse hyperechoic echostructure 
(bright liver), (2) increased liver echostructure 
compared with kidney, (3) vascular blurring, (4) 
deep attenuation. In a small retrospective study, 
Table 1. Causes of mild increases in ALT and AST levels10,11
Causes Diseases Work up
Hepatic 
causes
Alcohol abuse ALT/AST ratio > 2.0
Medications None
Chronic hepatitis B HBsAg, HBeAg, HBV DNA
Chronic hepatitis C Anti HCV, HCV RNA
Steatosis and non-
alcoholic steatosis 
hepatitis
Biopsy
Autoimmune
hepatitis
Serum protein electrophoresis 
Antinuclear antibody
Anti-smooth muscle antibody 
Hemochromatosis Transferrin saturation 45%
HFE gene analysis for C282Y 
mutation
Wilson’s disease Genetic analysis
Low serum copper, high urine 
copper
Kayser-Fleischer ring
α-antitrypsin
deficiency
A1AT phenotyping
Nonhepatic 
causes
Celiac sprue Antiendomysial and antigliadin 
antibodies
Inherited disorders of 
muscle metabolism
Aquired muscle 
disease
Creatinine kinase/aldolase 
level
Strenuous exercise
ALT: alanine aminotransferase; AST: aspartate transaminase; HBsAg: hepatitis 
B surface antigen; HBeAg: hepatitis B e-antigen; HCV: hepatitis C virus; DNA: 
deoxyribonucleic acid; RNA: ribonucleic acid
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a combination of these parameter allowed diagnosis 
of fatty liver with sensitivity of 83% and specificity of 
100%.14,15 The gold standard for diagnosing NAFLD is 
clinico-pathological correlation, with confirmation of 
steatosis by liver biopsy and exclusion of other causes 
(e.g. alcohol).16 
Drug-related hepatotoxicity
It is important to recognize the pattern of liver injury, 
since certain drugs tend to create injury predominantly 
according to one pattern or the other, these include: 
(1) hepatocellular (e.g. amiodarone, acetaminophen, 
allopurinol, isoniazid, statin, rifampicin, etc), 
with elevated ALT predominantly; (2) cholestatic 
(e.g. amoxicillin-clavulanic acid, chlorpromazine, 
clopidogel, irbesartan, etc), with elevated ALP and total 
bilirubin predominantly; (3) mixed (e.g. amitryptyline, 
captapril, clindamycin, enalapril, verapamil, etc) with 
elevated ALP and ALT predominantly. In most cases, 
there is no effective treatment other than stopping the 
drug and providing general supportive care. Prompt 
use of N-acetylcysteine after acetaminophen overdose 
and intravenous carnitine for valproate-induced 
mitochondrial injury are exceptions.3
Chronic Viral hepatitis
In chronic hepatitis B, AST and ALT may return to 
normal despite persistence of infection. Liver biopsy 
and treatment should be considered in patients with 
positive test for hepatitis virus, DNA and hepatitis B 
e antigen. The natural history of hepatitis C is quite 
variable. In acute HCV infection elevation in serum 
ALT levels occurs approximately 2-8 weeks after 
exposure. Although the definition of chronic hepatic 
injury by increased ALT is widely accepted, 15-50% 
patients with chronic hepatitis C have persistently 
normal ALT. Nafees et al, conducted a study to find out 
how many subjects with asymptomatic HCV infection 
have normal or elevated serum AST and ALT levels. 
They revealed that 90.76% and 87.45% of patients had 
elevated AST and ALT respectively.17 The majority of 
patients with persistent normal ALT had histologic 
evidence of chronic hepatitis on biopsy but, in general, 
had milder inflammation, less fibrosis, and lower rates 
of progression to cirrhosis than HCV patients with 
increased ALT. Patients infected with HCV genotypes 
2 and 3 had sustained virological response rates over 
80%, after treated by daily ribavirin and peg-IFN-α.18,19 
Therefore, it arises a question: should all patients 
with abnormal liver function tests in primary care 
be tested for chronic viral hepatitis? David et al, 
recommended that all patients should undergo viral 
test where a clear clinical indication of infection is 
present (e.g evidence of intravenous drug use) or all 
patients who originated from countries where viral 
hepatitis is prevalent.20
Autoimmune hepatitis
The presentation of autoimmune hepatitis is 
heterogeneous, and the clinical course may be 
characterized by periods of decreased or increased 
activity; thus, clinical manifestations are variable. 
The spectrum of presentation ranges from no symptoms to 
debilating symptoms and even fulminant hepatic failure. 
The laboratory abnormalities in general, aminotranferase 
elevations are more striking than abnormalities in 
bilirubin and alkaline phosphatase levels. A useful 
screening test is serum protein electrophoresis (more 
than 80% patients have hypergammaglobulinemia). 
Additional test that are commonly ordered include 
serologic test for antinuclear antibody (ANA), anti-
smooth muscle antibody (ASMA), and liver-kidney 
microsomal antibodies. Furthermore, a liver biopsy is 
essential to confirm the diagnosis.21,22 
Type 2 Diabetes 
Individuals with type 2 diabetes have a higher 
incidence of liver function test abnormalities than 
individuals who do not have diabetes. The most 
common abnormality is elevated ALT. Mild chronic 
elevation of aminotransferase often reflects underlying 
insulin resistance. Any diabetic patient found to have 
a mild chronic elevation of ALT, or elevation of ALT 
< 250 U/L for > 6 months should be screened for 
treatable causes of chronic liver disease, particularly 
hepatitis B, or C, and hemochromatosis, there is 
increased incidence of the diseases in type 2 diabetes. 
Elevation of aminotransferase within three times the 
upper limit of normal values is not a contraindication 
for starting oral diabetic or lipid modifying therapy. 
In contrast, antidiabetic agents have generally been 
shown to decrease ALT levels as tighter blood glucose 
levels are achieved.23
Alcohol Use
The diagnosis of alcohol abuse can be difficult 
because many patients conceal information about their 
alcohol use. This diagnosis is supported by the finding 
of ratio of AST to ALT > 2 : 1. In a study of a hundreds 
of patients who had histologically confirmed liver 
disorders, more than 90% of patients who had ratio AST 
to ALT > 2 : 1, had alcoholic liver disease. The increase 
ratio reflects primary the low serum activity of ALT 
in patients with alcoholic liver disease. This decrease 
is due to an alcohol-related deficiency of pyridoxal 
5-phosphatase. Measurement of γ-glutamyl-transferase 
may also be helpful in diagnosing alcohol use.21
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Other Causes
Hereditary hemocromatosis, Wilson’s disease and 
α-antitrypsin deficiency are sometimes detected in 
clinical practice. Hereditary hemochromatosis is a 
common genetic disorder. Cost effective screening 
starts with the measurement of serum iron and total 
binding capacity. A transferring-saturation value 
> 45% is suggestive of hemocromatosis. A liver 
biopsy should be performed in assessing hepatic iron 
and the severity of liver damage. Wilson’s disease, 
a genetic disorder of biliary copper excretion, may 
cause elevated aminotransferase levels in patients 
with no other symptom of the disease. In Wilson’s 
disease, serum ceruloplasmin will be reduced in 
approximately 85 % of affected patients. In 24-
hour urine collection, excretion of more than 100 
uq of copper/day is suggestive of Wilson’s disease. 
The diagnosis is usually confirmed by liver biopsy to 
measure hepatic copper levels. α-antitrypsin deficiency 
is an uncommon cause of chronic liver disease. 
Decreased level of α-antitrypsin can be detected 
either by direct measurement of serum levels or by 
the lack of a peak in α-globulin bands on serum protein 
electrophoresis. The best diagnosis is established by 
phenotype determination.10,21 Occult coelic sprue is 
recognized as a cause of raised aminotransferases. 
Antiendomysial and antigliadin antibodies are useful 
confirmatory tests.24 Elevated serum amonitransferase 
levels, especially AST levels, may be caused by 
disorders that affect organs or tissues other than 
the liver, with the most common affected organ being 
the striated muscle. Conditions or activities that can 
cause such elevations include subclinical inborn errors 
or muscle metabolism, acquired muscle disorders, such 
as polymyositis, and strenuous exercise (e.g. long-
distance running).21
Smita et al, reported a clinical case study, an 
asymptomatic patient, 66 years old female with 
persistent increase of aminotrasferase. A physical 
examination revealed a healthy appearing female 
with no obvious abnormalities. All laboratory studies 
revealed normal results (including ALT, except 
an isolated increase in AST (544 U/L). They also 
concluded that persistent increase of AST was caused 
by a macroenzyme form. Macroenzymes are usually 
present due to the formation of an autoantibody 
enzyme complex, which has a higher molecular mass 
and a delayed clearance that leads to an increase 
in the amount of circulating enzyme. Identifying 
and documenting macroenzymes help preventing 
additional expensive testing and treatment.25 
CLINICAL APPROACh
Through close clinical approach, the majority 
patients (92%) with chronically elevated liver function 
tests were able to be diagnosed with the etiologies of 
the liver disease by history taking, physical examination, 
blood tests.12 The history taking should be directed to 
identify risk factors for disease, with special attention 
on family history, medications, vitamin, herbal 
supplements, drug use, alcohol use, and blood product 
transfusions. The other significant health condition 
that can cause or augment liver transaminase elevation 
should be noted (type 2 diabetes, heart disease, thyroid 
disease, muscle disease, cancer) (Figure 1).6,26
About 4-6 weeks after that, repeating liver 
biochemical tests may be helpful to exclude spurious 
results. When more than one of these tests provide 
abnormal findings, or the findings are persistently 
abnormal on serial determinations, the probability of 
liver disease is high. When all test results are normal, 
the probability of missing occult liver disease is low.27
When the liver biochemical tests are still abnormal, 
other laboratories examination (ALT, AST, alkaline 
phosphates, bilirubin, albumin, prothrombin time, 
complete blood count, hepatitis A, B, C serologies and 
iron studies) should be done. Commonly, liver function 
tests are transiently abnormal after alcohol excess, 
minor viral illness, or drug reaction. An abnormal test 
result should be repeated after several weeks after 
lifestyle modification are conducted. Effective lifestyle 
modification includes complete abstinence from 
alcohol, control of diabetes and hyperlipidemia, weight 
loss in overweight, stopping hepatotoxic medications 
and supplements. In Sherwood et al, the abnormal test 
result resolved spontaneously in 38% of patients.5
Additional laboratory tests should be obtained 
when repeated liver biochemical were still elevated. 
Further serologic evaluation: ANA, anti-smooth 
muscle antibodies, ceruloplasmin, α-antitrypsin, 
antiendosmysial and anti-tissue transglutaminase 
antibodies, and imaging (ultrasound, CT, MRI, as 
indicated) could be done. Ultrasound of the liver is 
especially performed if fatty infiltration is suspected 
(obese individuals, diabetics and or hyperlipidaemic 
patients). 
The ability of clinicians deputes supported 
by laboratory and the liver imaging techniques 
to accurately diagnose patients with chronically 
abnormal liver test may be limited. In many instances 
imaging and biochemical testing cannot replace 
liver biopsy examination for definite determination 
of nature and extent of hepatic damage. Van Ness 
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et al, conducted a study to determine diagnostic 
usefulness of percutaneous liver biopsy in evaluating 
patients with chronically liver-associated enzymes. 
The ability to diagnose clinically fatty liver, chronic 
necroinflammatory disease, and alcoholic liver disease 
was 56%, 81% and 88%, respectively.28 In 8% of the 
patients with chronic abnormal ALT levels no cause 
is found.12 So, if liver test abnormalities cannot be 
explained by other findings, liver biopsy examination 
can help to exclude serious liver disease or disclose 
the nature and severity of liver disease. Liver biopsy 
can provide important prognostic and diagnostic 
information regarding the cause of the liver disease 
but should be performed only if the expected benefit 
exceeds the small risk of the procedure.  
CONCLUSION
Isolated alterations of biochemical markers 
of liver damage in seemingly healthy patient can 
present a challenge for the clinician. Mild elevation 
in liver chemistry tests such as ALT and AST can 
reveal serious underlying disease or have transient 
and benign etiologies. The majority patients with 
chronically elevated amonitransferase tests were able 
to be diagnosed with the etiologies of the liver disease 
by history taking, physical examination, and blood 
tests. The most common etiologies for chronic liver 
transaminase levels are alcohol use, non-alcoholic 
fatty liver disease, and viral hepatitis. In about 8% of 
patients with chronic abnormal ALT levels no cause 
was found. So, if liver test abnormalities cannot be 
Figure 1. Evaluation of increased serum transaminase levels6
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explained by other findings, liver biopsy examination 
can be considered to exclude serious liver disease or 
disclose the nature and severity of liver disease. 
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